Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849207 · ClinicalTrials.gov registry record · Phase 1
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
A Phase 1 study of Hematologic Malignancies, sponsored by Ronald Paquette.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT05849207: Recruiting Phase 1 study of Hematologic Malignancies, sponsored by Ronald Paquette.
NCT05849207 is a Phase 1 study of Hematologic Malignancies that is actively recruiting participants, run by Ronald Paquette. The registered enrollment target is 26 participants, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05849207, a Phase 1 study of Hematologic Malignancies, is actively recruiting participants, sponsored by Ronald Paquette.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
Primary Outcome
Evaluate the frequency of grade III/IV acute GVHD using Modified Keystone Criteria
Conditions Studied
Interventions
- DRUG Cyclophosphamide
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 1 |
What NCT05849207 shows while recruiting
NCT05849207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 2,711-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which Cyclophosphamide is the first listed.
NCT05849207 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05849207 about?
NCT05849207 is a clinical study titled "Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant". The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
What is the current status of trial NCT05849207?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2023-10-24. Estimated completion is 2028-07-01.
What conditions does trial NCT05849207 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT05849207?
The interventions under investigation include: Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT05849207?
This trial is sponsored by Ronald Paquette, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05849207 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05849207's enrollment target sits among peer trials
26 38th of 45 higher than 8 of 45 other Hematologic Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
RECRUITING · Phase 1
-
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI